VINC
Vincerx Pharma, Inc. [VINC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VINC Stock Summary
Top 10 Correlated ETFs
VINC
Top 10 Correlated Stocks
VINC
In the News
VINC Financial details
Company Rating
-
Market Cap
20.99M
Income
-39.4M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
42
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.74
Forward P/E
-
PEG
0.23
P/S
-
P/B
1.88
P/C
-
P/FCF
-0.64
Quick Ratio
2.47
Current Ratio
2.58
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.85
EPS next Y
-
EPS next Q
-
EPS this Y
-30.51%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-50%
-
-
-
-
SMA20
-83.33%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-152%
ROE
-131%
ROC
-3.01%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.61-9.372
52W High
-
52W Low
-
RSI
32
Rel Volume
0.31
Avg Volume
1.11M
Volume
341.57K
Perf Week
-14.85%
Perf Month
-89.25%
Perf Quarter
-5.39%
Perf Half Y
-17.33%
-
-
-
-
Beta
0.808
-
-
Volatility
0.04%, 2.41%
Prev Close
-5.39%
Price
0.8515
Change
-10.36%
Company Profile
- Volume Average 1.11M
- Market Capitalization 20.99M
- Employee 42
- CEO Dr. Ahmed M. Hamdy M.D.
- Headquarters Palo Alto,CA,US
- IPO Date 2020-05-27
-
Website
https://vincerx.com 
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
